According to GlaxoSmithKline's latest financial reports the company has a price-to-book ratio of 5.54.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2024-12-31 | N/A | -100% |
2023-12-31 | 4.68 | -20.37% |
2022-12-31 | 5.88 | 55.22% |
2021-12-31 | 3.79 | 17.06% |
2020-12-31 | 3.24 | -33.08% |
2019-12-31 | 4.83 | -76.01% |
2018-12-31 | 20.2 | 7.85% |
2017-12-31 | 18.7 | 21.55% |
2016-12-31 | 15.4 | 104.19% |
2015-12-31 | 7.53 | -44.45% |
2014-12-31 | 13.6 | 35.39% |
2013-12-31 | 10.0 | 3.07% |
2012-12-31 | 9.71 | 15.46% |
2011-12-31 | 8.41 | 24.2% |
2010-12-31 | 6.77 | 7.37% |
2009-12-31 | 6.31 | -20.44% |
2008-12-31 | 7.93 | 12.58% |
2007-12-31 | 7.04 | -12.13% |
2006-12-31 | 8.02 | -29.23% |
2005-12-31 | 11.3 | -4.99% |
2004-12-31 | 11.9 | 36.9% |
2003-12-31 | 8.71 | -28.47% |
2002-12-31 | 12.2 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Novartis NVS | 5.27 | -4.79% | ๐จ๐ญ Switzerland |
Pfizer PFE | 1.84 | -66.84% | ๐บ๐ธ USA |
Sanofi SNY | 1.50 | -72.93% | ๐ซ๐ท France |
Merck MRK | 8.81 | 59.12% | ๐บ๐ธ USA |
AstraZeneca AZN | 6.37 | 15.06% | ๐ฌ๐ง UK |
Teva Pharmaceutical Industries TEVA | 2.29 | -58.69% | ๐ฎ๐ฑ Israel |
Dynavax Technologies
DVAX | 2.37 | -57.12% | ๐บ๐ธ USA |